Tech Company Financing Transactions
Eiger BioPharmaceuticals Funding Round
On 11/23/2015, Eiger BioPharmaceuticals announced $6 million in funding from private investors.
Transaction Overview
Company Name
Announced On
11/23/2015
Transaction Type
Debt
Amount
$6,000,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed. SEC regulatory filing. Amount may include options, warrants or other securities. Contact technology company for investment details, if applicable. Not an offer or solicitation for the sale of securities or debt.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
2155 Park Blvd.
Palo Alto, CA 94306
USA
Palo Alto, CA 94306
USA
Phone
Website
Email Address
Overview
Eiger is a biopharmaceutical company developing new antiviral agents against novel targets in the treatment of hepatitis.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Cory
Chief Financial Officer
Sri Ryali
VP - Bus. Development
Eldon Mayer
VP - General Counsel
Stephana Patton
VP - Sales
James Shaffer
Browse more venture capital transactions:
Prev: 11/23/2015: Ruby Ribbon venture capital transaction
Next: 11/23/2015: LogicMonitor venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to record all VC transactions involving tech companies. All VC database entries reported here come from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs